| Autor: |
Millstine, Denise M., Kling, Juliana M. |
| Zdroj: |
Med; December 2024, Vol. 5 Issue: 12 p1459-1460, 2p |
| Abstrakt: |
In the OASIS 1 and 2 trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, was compared to placebo in women aged 40–65 with moderate to severe menopausal vasomotor symptoms (VMSs) at multiple sites over 26 weeks. Elinzanetant significantly reduced VMS frequency and severity and improved sleep disturbance and menopause-related quality of life compared to placebo with few adverse side effects.1 |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
